(Q43517854)

24 November 2017

title

Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis (English)

1 reference

24 November 2017

1 reference

H Tomková

1

1 reference

24 November 2017

M Pospíšková

2

1 reference

24 November 2017

M Zábojníková

3

1 reference

24 November 2017

M Kohoutek

4

1 reference

24 November 2017

M Serclová

5

1 reference

24 November 2017

M Gharibyar

6

1 reference

24 November 2017

J Sternberský

7

1 reference

24 November 2017

publication date

31 October 2011

1 reference

Journal of the European Academy of Dermatology and Venereology

24 November 2017

published in

1 reference

24 November 2017

volume

27

1 reference

24 November 2017

issue

4

1 reference

24 November 2017

page(s)

514-519

1 reference

Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04324.X

Skin toxicities associated with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04324.X

Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04324.X

The epidermal growth factor receptor system in skin repair and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04324.X

Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04324.X

Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04324.X

1,4-Naphthoquinones as inducers of oxidative damage and stress signaling in HaCaT human keratinocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04324.X

Cetuximab-induced cutaneous toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04324.X

Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04324.X

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04324.X

10.1111/J.1468-3083.2011.04324.X

21 January 2018

Identifiers

DOI

1 reference

24 November 2017

1 reference